Structural and Functional Analysis of Excised Skins and Human Reconstructed Epidermis with Confocal Raman Spectroscopy and in Microfluidic Diffusion Chambers.
confocal Raman spectroscopy
human-reconstructed epidermis
hydration
skin barrier
skin penetration
skin-on-a-chip microfluidic device
transdermal delivery
transepidermal water loss
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
13 Aug 2022
13 Aug 2022
Historique:
received:
14
07
2022
revised:
04
08
2022
accepted:
11
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Several ex vivo and in vitro skin models are available in the toolbox of dermatological and cosmetic research. Some of them are widely used in drug penetration testing. The excised skins show higher variability, while the in vitro skins provide more reproducible data. The aim of the current study was to compare the chemical composition of different skin models (excised rat skin, excised human skin and human-reconstructed epidermis) by measurement of ceramides, cholesterol, lactate, urea, protein and water at different depths of the tissues. The second goal was to compile a testing system, which includes a skin-on-a-chip diffusion setup and a confocal Raman spectroscopy for testing drug diffusion across the skin barrier and accumulation in the tissue models. A hydrophilic drug caffeine and the P-glycoprotein substrate quinidine were used in the study as topical cream formulations. The results indicate that although the transdermal diffusion of quinidine is lower, the skin accumulation was comparable for the two drugs. The various skin models showed different chemical compositions. The human skin was abundant in ceramides and cholesterol, while the reconstructed skin contained less water and more urea and protein. Based on these results, it can be concluded that skin-on-a-chip and confocal Raman microspectroscopy are suitable for testing drug penetration and distribution at different skin layers within an exposition window. Furthermore, obese human skin should be treated with caution for skin absorption testing due to its unbalanced composition.
Identifiants
pubmed: 36015315
pii: pharmaceutics14081689
doi: 10.3390/pharmaceutics14081689
pmc: PMC9415586
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : the Conseil Régional Centre-Val de Loire (project MINIONs, ARD Cosmetosciences
ID : N° 2020-00141275 and APR-IR-project UFO N°2020-00138875
Organisme : National Research, Development, and Innovation Fund of Hungary, financed under the National Bionics Program
ID : TKP2021-EGA-42
Références
Atherosclerosis. 2005 Jul;181(1):167-73
pubmed: 15939069
Int J Pharm. 2009 Mar 31;370(1-2):61-7
pubmed: 19071202
Eur J Pharm Biopharm. 2018 Sep;130:214-223
pubmed: 29981829
Pharm Res. 2005 Jun;22(6):842-6
pubmed: 15948026
J Biomol Screen. 2011 Sep;16(8):886-94
pubmed: 21832259
Atherosclerosis. 2003 Dec;171(2):255-8
pubmed: 14644394
APL Bioeng. 2021 Jul 08;5(3):030901
pubmed: 34258497
J Invest Dermatol. 2018 Aug;138(8):1774-1784
pubmed: 29550417
Pharmaceutics. 2019 Sep 02;11(9):
pubmed: 31480652
Int J Mol Sci. 2022 Feb 14;23(4):
pubmed: 35216228
Pharmaceutics. 2021 May 16;13(5):
pubmed: 34065623
J Biophotonics. 2018 Jun;11(6):e201700355
pubmed: 29460347
Int J Pharm. 2017 Apr 15;521(1-2):365-373
pubmed: 28242377
J Invest Dermatol. 2001 Mar;116(3):434-42
pubmed: 11231318
Pharmaceutics. 2020 Nov 25;12(12):
pubmed: 33255623
J Colloid Interface Sci. 2019 Feb 1;535:227-238
pubmed: 30300812
J Lipid Res. 2007 Dec;48(12):2531-46
pubmed: 17872588
Biophys Chem. 2010 Aug;150(1-3):144-56
pubmed: 20457485
Small. 2020 Oct;16(39):e2002515
pubmed: 33460277
J Control Release. 2006 Feb 21;110(3):542-56
pubmed: 16380188
Lipids. 2009 Mar;44(3):291-5
pubmed: 19184160
J Control Release. 2008 Nov 12;131(3):198-204
pubmed: 18725258
Skin Pharmacol Appl Skin Physiol. 2001 Mar-Apr;14(2):117-28
pubmed: 11316970
Adv Drug Deliv Rev. 2021 Aug;175:113802
pubmed: 34015420
Pharmaceutics. 2021 Nov 03;13(11):
pubmed: 34834264
Curr Probl Dermatol. 2018;54:64-70
pubmed: 30130772
Drug Deliv Transl Res. 2022 Aug;12(8):1811-1828
pubmed: 34755281
J Biomol Screen. 2013 Apr;18(4):430-40
pubmed: 23204072
Acta Pol Pharm. 2006 May-Jun;63(3):159-67
pubmed: 20085219
J Invest Dermatol. 2009 Jan;129(1):31-40
pubmed: 19078986
Atherosclerosis. 2005 Aug;181(2):371-3
pubmed: 16039292
Biomed Microdevices. 2016 Aug;18(4):67
pubmed: 27422107
Molecules. 2018 Apr 10;23(4):
pubmed: 29642579
Curr Protoc Pharmacol. 2020 Sep;90(1):e78
pubmed: 32790966
Langmuir. 2019 Nov 26;35(47):15376-15388
pubmed: 31698908
J Pharm Sci. 1991 May;80(5):424-7
pubmed: 1880719
Int J Cosmet Sci. 2009 Apr;31(2):97-118
pubmed: 19175433
J Lipids. 2018 Sep 2;2018:5954034
pubmed: 30245886
Pharmaceutics. 2020 Aug 25;12(9):
pubmed: 32854319
Sci Rep. 2017 Nov 16;7(1):15712
pubmed: 29146971
Regul Toxicol Pharmacol. 2022 Mar;129:105098
pubmed: 34953932
Expert Opin Drug Deliv. 2020 Feb;17(2):145-155
pubmed: 31910342
J Pharm Sci. 2017 Sep;106(9):2632-2641
pubmed: 28479358
Pharmaceutics. 2021 Mar 24;13(4):
pubmed: 33804924
Toxicol In Vitro. 2018 Aug;50:439-449
pubmed: 29326048
J Control Release. 2017 Feb 10;247:86-105
pubmed: 28024914